Table 2 Changes in patient’s assessments of disease activity, pain and morning stiffness and odds ratios for an increase of at least 20 mm in visual analogue scales for these outcomes during the presence of a flare, compared to the absence of a flare (reference category)
Change in VASda | Change in VASpain | Change in VASms | ||||
|---|---|---|---|---|---|---|
Median | IQR | Median | IQR | Median | IQR | |
No flare A | 0 | −8 to 5 | 0 | −8 to 5 | 0 | −8 to 6 |
Flare A | 17 | 3 to 40 | 17 | 3 to 35 | 11 | 0 to 29 |
No flare B | 0 | −8 to 5 | 0 | −8 to 5 | 0 | 8 to 6 |
Minor flare B | 7 | −4 to 20 | 5 | −4 to 18 | 5 | −5 to 16 |
Major flare B | 18 | 4 to 41 | 18 | 3 to 37 | 12 | 0 to 31 |
Increase in VASdaa | Increase in VASpaina | Increase in VASmsa | ||||
ORb | 95 % CI | ORb | 95 % CI | ORb | 95 % CI | |
No flare A | ref | ref | ref | ref | ref | Ref |
Flare A | 8.47 | 7.30–9.83 | 8.35 | 7.20–9.69 | 5.63 | 4.84–6.55 |
No flare B | ref | ref | ref | ref | ref | Ref |
Minor flare B | 3.10 | 2.35–4.07 | 2.84 | 2.15–3.75 | 2.32 | 1.73–3.12 |
Major flare B | 8.76 | 7.46–10.28 | 8.59 | 7.32–10.08 | 5.90 | 5.01–6.94 |